Could two antibodies and a pill help women control HIV without daily drugs?
NCT ID NCT05281510
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two lab-made antibodies (VRC07-523LS and CAP256V2LS) and an immune-boosting pill (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy. The goal was to see if the regimen is safe and might help control the virus after stopping daily meds. Participants were monitored for side effects and viral rebound.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VRC07-523LS and CAP256V2LS (antibodies) plus vesatolimod (immune stimulant)
What this could lead to
If successful, this combination might help control HIV without daily pills, pointing toward long-term remission.
What could go wrong
This is a small, early-phase safety study with only 20 women. It may not lead to a practical treatment, and side effects from the immune stimulant or antibodies are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
FRESH Clinical Research Site: Females Rising through Education, Support and Health
Umlazi, 4066, South Africa